Navigation Links
EpiCept Reports Regulatory Progress on Ceplene(TM)
Date:9/17/2007

Application for AML Remission Maintenance Therapy

Advances on Schedule Following Meeting with EMEA

TARRYTOWN, N.Y., Sept. 18 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today reported that the assessment of its European Union centralized marketing authorization application for its lead oncology product Ceplene(TM) is advancing according to the anticipated regulatory timetable following a meeting yesterday. Ceplene (histamine dihydrochloride) has demonstrated important clinical benefit in the maintenance of remission for patients with Acute Myeloid Leukemia (AML).

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

EpiCept's Marketing Authorization Application (MAA) for Ceplene has reached the next important step in its assessment by the Committee for Human Medicinal Products (CHMP). Specifically, EpiCept submitted full responses to the Day 120 Consolidated List of Questions. EpiCept's staff and expert consultants met on September 17 with EMEA officials and CHMP representatives to discuss these responses. Included with the Day 120 response documentation, EpiCept has provided data on Ceplene's effect on quality of life and on long term follow up of at least five years on leukemia-free survival for AML patients.

"We are pleased to have reached the latest regulatory milestone for Ceplene in the EU, and to be closer to our goal of providing hematologists with the first remission maintenance immunotherapy for AML patients," stated Jack Talley, President and Chief Executive Officer of EpiCept. "EpiCept outlined to the EMEA and CHMP representatives how the data package for Ceplene supports approval. We look forward to working with the regulators to complete their assessment. We are enthusiastic about the potential of Ceplene, which in our pivotal trial increased the long-term, disea
'/>"/>

SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
2. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014   Easy Breathe , the fastest ... announced that it now offers the revolutionary AirSense ... the first sleep apnea therapy devices with internal cellular ... to track and share real-time data on each user,s ... CPAP therapy.  In addition, the internal modem allows the ...
(Date:9/30/2014)... ORANGE , N.J. and NEW BRUNSWICK, N.J., Sept. 30, ... affiliation agreement that allows Kessler Foundation and New ... advance biomedical research, education and patient care programs ... president and chief executive officer of Kessler Foundation ... New Jersey Health Foundation. "The experience ...
(Date:9/30/2014)... , Sept. 30, 2014 The Eastern European ... established medical-device providers as well as new medical-device manufacturers ... while simultaneously looking at ways to reduce the cost ... distributors is one of the effective means to achieve ... distribution market in Eastern European and provides profiles of ...
Breaking Medicine Technology:Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3
(Date:9/30/2014)... New York, NY (PRWEB) September 30, 2014 ... and falling demand have hampered growth in the ... Popular diets have caused consumers to moderate their ... growing consumer preferences for premium varieties shrunk the ... bread products. Successful operators proactively responded by introducing ...
(Date:9/30/2014)... been awarded a three-year $1.7 million grant from ... new imaging technologies and data analysis techniques that ... of neurons in the brain interact to process ... the precise interactions between millions of nerve cells ... alterations in these interactions that may be responsible ...
(Date:9/30/2014)... September 30, 2014 The American ... to help diabetics curb their sweet tooth, but the ... this September, suggests that zero-calorie sweeteners may actually ... diabetes. , The Weizmann Institute of Science in ... artificial sweeteners to mice, the mice developed glucose intolerance. ...
(Date:9/30/2014)... 2014 Regenerative Medicine Solutions (RMS) is ... in Nashville, Tennessee. RMS welcomes the launch of an ... expansion of a new treatment center for the Lung ... Apnea Institute to Nashville, the hope is to bring ... both diagnosed and undiagnosed. With Nashville being a hub ...
(Date:9/30/2014)... 30, 2014 (HealthDay News) -- Medicare should cover low-dose ... risk for the disease, a coalition of more than ... which includes the Lung Cancer Alliance, the Society of ... Cancer Society and the American Society of Clinical Oncology, ... the U.S. Centers for Medicare & Medicaid Services (CMS). ...
Breaking Medicine News(10 mins):Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Regenerative Medicine Solutions Expanding 2Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2
... Small Business Committee Leaders to Press for Affordable ... 24 In advance of tomorrow,s,Finance Committee hearing ... Kerry (D-Mass.) and Olympia J. Snowe (R-Maine), Chairman ... and Entrepreneurship,sent a letter to the leaders of ...
... from a Phase I/II clinical trial of a novel ... In 26 patients with advanced solid tumors, treatment with ... yielding plasma concentrations above the expected therapeutic threshold, says ... in Montreal, Canada. Thallion has produced and tested ...
... seven exceptionally talented and creative investigators in the early ... Health Science (NIEHS), part of the National Institutes of ... made under NIEHSs Outstanding New Environmental Sciences (ONES) program. ... of our efforts to help establish the careers of ...
... supports vitamins for respiratory health , , WEDNESDAY, Oct. 24 (HealthDay ... of drinks a day may help keep the doctor away, ... daily dose of alcohol helps the heart, this study suggests ... for smokers. , "This is the biggest study that,s ever ...
... Oct. 24 Thelen Reid Brown Raysman &,Steiner ... group has,successfully assisted long-time client The Doctors Company ... major provider of healthcare liability,insurance, for an aggregate ... share in cash. (Logo: http://www.newscom.com/cgi-bin/prnh/20071016/AQTU238LOGO ) ...
... trend, PHILADELPHIA, Oct. 24 Governor Edward ... Reduction of Error,Fund (Mcare) claims have dropped by ... result of reforms, more insurers are writing malpractice ... when it comes to medical malpractice,",Governor Rendell said ...
Cached Medicine News:Health News:Kerry, Snowe Push Finance Committee on Small Business Health Care 2Health News:Kerry, Snowe Push Finance Committee on Small Business Health Care 3Health News:Phase I pharmacokinetic study of ECO-4601, a novel bifunctional targeting agent 2Health News:NIEHS awards outstanding new environmental scientists 2Health News:Drink or Two a Day May Help Lungs 2Health News:Drink or Two a Day May Help Lungs 3Health News:Drink or Two a Day May Help Lungs 4Health News:Thelen Assists The Doctors Company in Acquisition of SCPIE Holdings Inc. 2Health News:Governor Rendell Says Mcare Claims and Costs Are 50 Percent Lower Than in 2003 2
The CK method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase activity in serum and plasma...
For the quantitative in vitro determination of Cholesterol in serum and plasma....
For the quantitative in vitro determination of Alanine Aminotransferase (ALT) in serum and plasma....
... introduces the Tag-It™ Cystic Fibrosis Kit, the ... genotyping. With validated performance criteria, this highly ... superior mutation coverage for carrier screening in ... in newborns. ,The Tag-It™ Cystic Fibrosis ...
Medicine Products: